Prognostic markers in bladder cancer

Current Opinion in Urology

Volumn 6, Issue 5, 1996, Pages 267-271

  Griffiths, T R Leyshon ^a,b   Neal, David E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; PROTEIN P53; TUMOR MARKER; UVOMORULIN;

BLADDER CANCER; CANCER GRADING; CYSTECTOMY; GENE DELETION; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 10244255051     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199609000-00008     Document Type: Short Survey

References (46)

1. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M: Muscularis • mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995, 45:47-53. T1 bladder tumours which invade deep to the muscularis propria are more likely to progress, and these patients have a reduced survival.
2. Colombel M, De Launoit Y, Bellot J, Kiss R, Abbou C, Chopin D: Prognostic evaluation of morphonuclear parameters in superficial and invasive bladder cancer. Br J Urol 1995, 75:364-369.
3. Van Velthoven R, Petein M, Oosterlinck WJ, Roels H, Pasteels JL, Schulman C, Kiss R: The use of digital image analysis of chromatin texture in Feulgen-stained nuclei to predict recurrence of low grade superficial transitional cell carcinoma of the bladder. Cancer 1995, 75:560-568.
4. Kruger S, Muller H: Correlation of morphometry, nucleolar organizer • regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 1995, 75:480-484. In moderately differentiated tumours, Ki67 antigen was more helpful than the other three proliferation markers in defining Ta tumours from T1-T4 tumours.
5. Griffiths TRL, Mellon JK, Pyle GA, Shenton BK, Neal DE: P53 and • ploidy assessed by flow cytometry in bladder washings. Br J Urol 1995, 76:575-579. Analyzing pure urothelial cells (cytokeratin-positive) improves the detection of DNA abnormalities in bladder washings.
6. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin of bladder cancer. N Engl J Med 1992, 326:737-740.
7. Lunec J, Challen C, Wright C, Mellon K, Neal DE: c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 1992, 339:439-440.
8. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R: A prospective European Organisation for Research and Treatment of Cancer Genitourinary group randomised trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993, 149:749-752.
9. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993, 53:3241-3245.
10. Banks RE, Porter WH, Whelan P, Smith PH, Selby PJ: Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol 1995, 48:179-180.
11. Griffiths TRL, Brotherick I, Bishop RI, White MD, McKenna DM, Horne • CHW, Shenton BK, Neal DE, Mellon JK: Cell adhesion molecules in bladder cancer: soluble E-cadherin correlates with predictors of recurrence. Br J Cancer 1996, (in press). Elevated levels of soluble E-cadherin taken pre-operatively from patients with TCC were associated with multifocal tumours at presentation and recurrence at 3 months.
12. Parmar MKB, Freedman LS, Hargreave TB, Tolley DA: Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J Urol 1989, 142:284-288.
13. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J: Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathol 1995, 27:169-174.
14. Mellon K, Wright C, Kelly P, Home CH, Neal DE: Long-term outcome • related to epidermal growth factor receptor status in bladder cancer. J Urol 1995, 153:919-925. In this prospective study, EGFr status was a strong independent predictor of progression and survival. It appeared to be a particularly good marker of progression in T1G3 disease.
15. Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Hofner K, Tan • HK, Jonas U: P53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995, 31A:2243-2247. In this series of patients with muscle-invasive bladder cancer, all treated with radical cystectomy, p53 accumulation was an independent predictor of survival.
16. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz • PK, Cordon-Cardo C, Scher HI: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995, 13:1384-1390. Even in patients with muscle-invasive bladder cancer treated with neoadjuvant MVAC, p53 accumulation was not overshadowed by tumour stage.
17. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993, 85:53-59.
18. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995, 71:201-205.
19. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264.
20. Sarkis AS, Dalbagni G, Cordon-Cardo C: Association of p53 nuclear overexpression and tumour progression in carcinoma in situ of the bladder. J Urol 1994, 152:388-392.
21. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
22. Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N: p53 gene mutation in recurrent superficial bladder cancer. J Urol 1995, 153:1711-1715.
23. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, •• Nichols PW: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603-1612. In patients with muscle-invasive TCC (n=164), tumour angiogenesis, as determined by the immunohistochemical assessment of microvessel density provided independent prognostic information.
24. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994, 74:762-766.
25. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumour suppressor gene on chromosome 9. Oncogene 1993, 8:1083-1085.
26. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial •• allelotype of carcinoma in situ of the human bladder. Cancer Res 1995, 55:5213-5216. LOH of chromosome 9 occurred in 77% of CIS lesions thereby disputing earlier reports that this genetic event was less common in CIS lesions than in papillary superficial tumours. LOH of chromosome 14q occurs commonly in CIS compared with papillary superficial tumours.
27. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumour types. Science 1994, 264:436-440.
28. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
29. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Elby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994, 265:415-416.
30. Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzalez F, Tsai YC, Jones PA: p16 gene in uncultured tumours [Letter]. Nature 1994, 370:183-184.
31. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo J, Mao L, Herath J, Jenkins R, Westra W, et al.: High frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 1995, 11:210-212.
32. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, •• Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumours. J Natl Cancer Inst 1995, 87:1524-1529. The presence of two candidate tumour-suppressor genes at the 9p21 locus encoding p16 and p15 may explain the unusually high frequency of homozygous deletion on this chromosome. Indeed this study group demonstrate that coincident deletion of p16 and p15 genes in primary bladder cancer is common.
33. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, Chard T: • Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996, 77:61-69. An elevated pretreatment level of urinary βhCG corrected with respect to creatinine is a marker of poor prognosis in muscle-invasive bladder cancer and often associated with occult metastases.
34. Lazar V, Diez SG, Laurent A, Giovangrandi Y, Radvanyi F, Chopin D, •• Bidart JM, Bellet D, Vidaud M: Expression of human chorionic gonadotropin beta subunit genes in superficial and invasive bladder carcinomas. Cancer Res 1995, 55:3735-3738. Whereas hCG β7, 5, 8, and 3 messenger RNA were commonly detected in T1 and muscle-invasive tumours, only hCG β7 was found in Ta tumours and normal urothelium. This may explain previous reports of elevated βhCG levels in the sera and urine of patients with high stage and high grade disease.
35. Sires C, Neely S, Skinner D: Leukemoid reaction In a patient with bladder and prostate cancer. J Urol 1986, 135:366-367.
36. Mizutani Y, Okada Y, Terachi T, Kakehi Y, Yoshida O: Serum • granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies. Br J Urol 1995, 76:580-586. A positive correlation was found between elevated serum G-CSF levels and white blood cell counts. Serum G-CSF may arise from stimulated production by bladder cancer cells; elevated levels might be associated with a poor prognosis.
37. Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Nishi • T, Amano Y: Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1995,55:3438-3443. G-CSF is shown to act on G-CSF receptors on bladder cell lines resulting in proliferation of the cultured cancer cells.
38. Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL: An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. J Urol 1995, 154:237-241.
39. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, De-Groot N, Hochberg A: The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995, 45:335-338.
40. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, Abi-Aad A, Van Cangh P, Abbou CC, Chopin D, Boon T: Expression of AMGE genes in transitional cell carcinomas of the urinary bladder. Int J Cancer 1995, 64:60-64.
41. King ED, Matteson J, Jacobs SC, Kypnanou N: Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder association with tumour progression. J Urol 1996, 155:316-320.
42. Morris SB, Gordon EM, Shearer RJ, Woodhouse CR: Superficial bladder cancer for how long should a tumour-free patient have check cystoscopies? Br J Urol 1995, 75:193-196.
43. O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 1995, 76:311-314.
44. Korman HJ, Peabody JO, Cerny JC, Farah RN, Jiping Y, Avraham R: Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J Urol 1996, 155:346-349.
45. D'Hallewin MA, Baert L: Initial evaluation of the bladder tumour • antigen test in superficial bladder cancer. J Urol 1996, 155:475-476. Early results suggest that the bladder tumour antigen test is superior to bladder washing cytology in diagnosing superficial papillary bladder cancer but not CIS.
46. Mansour OA, Shouman SA, Khafagy M, Basma H, Liebmann PM, • Schauenstein K, el-Ahmady O: Urinary CA 19.9 as marker for bladder cancer. Lancet 1995, 346:512-513. Urinary levels of CA19.9 corrected for creatinine were significantly higher in patients with bladder cancer than control patients including those with schistosomiasis. More importantly, there was virtually no overlap between the two groups.